Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLCs registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hong Kong Consumer Group Counts Adulterated Herbal Medicine

This article was originally published in PharmAsia News

Executive Summary

Hong Kong's Consumers' Foundation tested 150 of China's herbal medicines last year and found 14.7 percent of them to contain not just traditional Chinese medicines, but also Western ingredients or heavy metal. The testing found 71 of 167 samples contained lead, 61 mercury and 40 cadmium. The foundation found that four of six samples found to be adulterated were from martial arts studios. (Click here for more

You may also be interested in...



Illegal Drug/Device Products Among Seizures By US/Indian Operation

Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.

Pfizer Launches Biosimilar Trastuzumab In US

Pfizer has confirmed the launch of its Trazimera trastuzumab biosimilar in the US. The rival to Herceptin will compete against not only the brand but also against two other biosimilars, with more on the way.

Deals Shaping The Medical Industry, February 2020

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.

UsernamePublicRestriction

Register

SC070979

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel